Figure 7: Comparison between the sensitivity of molecular MRI and fluorescent imaging in detecting micrometastases.
From: MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent
(a) Whole-body distribution of metastatic tumours (GFP), and Cy5.0 (CREKA-Cy5.0) binding or MRI tumour enhancement by CREKA-Tris(DOTA-Gd)3 (positive) tumours after segmentation. (b) Size distribution of metastatic tumours in mice after orthotopic cancer cell inoculation. (c) Sensitivity of molecular MRI in detecting micrometastases, based on volumes of 82 metastatic tumours analysed.
